17?-estradiol-mediated elevation of peripheral white blood cell count observed during estramustine phosphate therapy for prostate cancer

How to Cite:Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, et al. 17?-estradiol-mediated elevation of peripheral white blood cell count observed during estramustine phosphate therapy for prostate cancer. Int J Endocrinol Metab. 2011;9(4):. doi: https://doi.org/10.5812/Kowsar.1726913X.2246

Abstract

Background: In 1983, Daponte et al. first reported an increase in the peripheral white blood cell (WBCs) counts of prostate cancer patients treated with estramustine phosphate (EMP) therapy.
Objectives: In order to confirm Daponte’s observation, we reviewed the clinical data of prostate cancer patients treated with EMP. We also examined the association between WBC counts and 17β-estradiol levels throughout the duration of the EMP therapy.
Patients and Methods: The study population comprised of 66 prostate cancer patients who were being treated with EMP. The complete blood count with a differential WBC count and the levels of serum 17β-estradiol and C-reactive protein measured during the therapy were compared with the baseline levels. The correlation between serum 17β-estradiol level and WBC count was calculated using the Pearson correlation test.
Results: We observed that the total WBC and the neutrophil counts were significantly elevated during the therapy. The serum 17β-estradiol level significantly correlated with the WBC count (r2 = 0.031, P = 0.002). The granulocyte colony-stimulating factor levels measured during therapy were approximately 2-fold higher than the upper limit and decreased after cessation of the treatment (P = 0.037).
Conclusions: We successfully confirmed Daponte’s observation. The increase in WBC counts was possibly attributable to elevated serum 17β-estradiol levels.

Please cite this paper as:
Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, et al. 17β-Estradiol-Mediated Elevation of Peripheral White Blood Cell Count During Estramustine Phosphate Therapy for Prostate Cancer. Int J Endocrinol Metab. 2011; 9(4):347-51. DOI: 10.5812/Kowsar.1726913X.2246

Keywords

Fulltext

Full text is available in PDF

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 2
Last Update: 1 month ago
Scopus by Title: 0
Last Update: 1 month ago
Scopus by Title (Ref): 0
Last Update: 1 month ago
CrossRef: 2
Last Update: 6 days ago

Metrics

Licensing and reuse information

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Motofumi Suzuki:[PubMed][Scholar]
Tetsuya Fujimura:[PubMed][Scholar]
Hiroshi Fukuhara:[PubMed][Scholar]
Yutaka Enomoto:[PubMed][Scholar]
Hiroaki Nishimatsu:[PubMed][Scholar]
Akira Ishikawa:[PubMed][Scholar]
Haruki Kume:[PubMed][Scholar]
Yukio Homma:[PubMed][Scholar]
Tadaichi Kitamura:[PubMed][Scholar]

Research Institute for Endocrine Sciences

Outlines

17?-estradiol-mediated elevation of peripheral white blood cell count observed during estramustine phosphate therapy for prostate cancer

Abstract

Fulltext

Crossmark

Checking

Last Update: 1 month ago

Last Update: 1 month ago

Last Update: 1 month ago

Last Update: 6 days ago